熱門資訊> 正文
Eikon Therapeutics，Inc. GAAP每股收益为-1.63美元，低于0.03美元
2026-08-14 04:59
- Eikon Therapeutics, Inc. press release (EIKN): Q2 GAAP EPS of -$1.63 misses by $0.03.
- As of June 30, 2026, Eikon had cash, cash equivalents, and marketable securities of $531.2 million. Eikon expects its current cash, cash equivalents, and marketable securities to fund operations into the second half of 2027.
More on Eikon Therapeutics, Inc.
- Eikon Therapeutics: Behind The Rough Debut
- Eikon Therapeutics: Buy TLR Combinatory Potential Only After Lock-Up Expiry
- Eikon Therapeutics: Initiating Coverage With A Cautious Buy Rating
- Historical earnings data for Eikon Therapeutics, Inc.
- Financial information for Eikon Therapeutics, Inc.
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
